Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.33 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.33 |
| ▸ | CETP | P11597 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3063503 | 0.70 | PRCP (0.57) | HDAC4KDM1ATRPM8 | |
| SCHEMBL18559751 | 0.68 | HRH3 (0.38) | HDAC4KDM1ATRPV4TRPM8KCNH2 | |
| SCHEMBL19599023 | 0.65 | CHRNB2 (0.49) | HDAC4TRPV4KCNH2HRH3 | |
| SCHEMBL17525143 | 0.65 | TRPV4 (0.39) | HDAC4TRPV4KCNH2SLC6A3TAAR1 | |
| SCHEMBL29761449 | 0.65 | TRPV4 (0.39) | HDAC4TRPV4KCNH2SLC6A3TAAR1 | |
| SCHEMBL24540921 | 0.65 | TRPV4 (0.39) | HDAC4TRPV4KCNH2SLC6A3TAAR1 | |
| SCHEMBL31512134 | 0.64 | MEN1 (0.50) | HDAC4TRPV4HRH3 | |
| SCHEMBL23891889 | 0.64 | MEN1 (0.50) | HDAC4TRPV4HRH3 | |
| SCHEMBL25145866 | 0.64 | HTR2C (0.57) | TRPV4KCNH2HRH3 | |
| SCHEMBL20757589 | 0.63 | TRPV4 (0.46) | HDAC4TRPV4KCNH2SLC6A3TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200392132-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2020-12-17 | — | — | US | disclosed |
| US-20190218217-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives as PI3Kdelta inhibitors | NOVARTIS AG (CH) | 2019-07-18 | — | — | US | disclosed |
| US-20190040061-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2019-02-07 | — | — | US | disclosed |
| US-20180265509-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2018-09-20 | — | — | US | disclosed |
| US-9949979-B2 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2018-04-24 | — | — | US | disclosed |
| US-20170267678-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2017-09-21 | — | — | US | disclosed |
| US-20170022199-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2017-01-26 | — | — | US | disclosed |
| US-9499536-B2 | Tetrahydro-pyrido-pyrimidine derivatives | NOVARTIS AG (CH) | 2016-11-22 | — | — | US | disclosed |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | NOVARTIS AG (CH) | 2015-12-03 | — | — | US | disclosed |
| EP-2790705-A1 | USE OF INHIBITORS OF THE ACTIVITY OR FUNCTION OF PI3K | Novartis AG (CH) | 2014-10-22 | — | — | EP | disclosed |
| EP-2590974-B1 | TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2014-05-21 | — | — | EP | disclosed |
| US-20140128370-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2014-05-08 | — | — | US | disclosed |
| US-8653092-B2 | Tetrahydro-pyrido-pyrimidine derivatives | NOVARTIS AG (CH) | 2014-02-18 | — | — | US | disclosed |
| WO-2013088404-A1 | Use of inhibitors of the activity or function of PI3K | NOVARTIS AG (CH) | 2013-06-20 | — | — | WO | disclosed |
| EP-2590974-A1 | TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | Novartis AG (CH) | 2013-05-15 | — | — | EP | disclosed |
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | NOVARTIS AG (CH) | 2012-03-15 | — | — | US | disclosed |
| WO-2012004299-A1 | TETRAHYDRO-PYRIDO-PYRIMIDINE DERIVATIVES | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040061-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | HDAC4 3456/4885KDM1A 2583/4885TRPV4 4661/4885 |
| US-20170267678-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | HDAC4 3456/4885KDM1A 2583/4885TRPV4 4661/4885 |
| US-20120065183-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | HDAC4 3456/4885KDM1A 2583/4885TRPV4 4661/4885 |
| US-20200392132-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | HDAC4 3456/4885KDM1A 2583/4885TRPV4 4661/4885 |
| US-20140128370-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | HDAC4 3456/4885KDM1A 2583/4885TRPV4 4661/4885 |
| US-20190218217-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives as PI3Kdelta inhibitors | PIK3CA, PIK3CD, PIK3CB | HDAC4 3741/4885KDM1A 2691/4885TRPV4 4730/4885 |
| US-20170022199-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | HDAC4 3456/4885KDM1A 2583/4885TRPV4 4661/4885 |
| US-20150342951-A1 | Use of Inhibitors of the Activity or Function of PI3K | TLR9, PIK3CD, PIK3R5 | HDAC4 416/4885KDM1A 1463/4885TRPV4 3671/4885 |
| US-20180265509-A1 | Tetrahydro-Pyrido-Pyrimidine Derivatives | PIK3CA, TYMP, TYMS | HDAC4 3456/4885KDM1A 2583/4885TRPV4 4661/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.